Wed, December 8, 2010
Tue, December 7, 2010
Mon, December 6, 2010
Fri, December 3, 2010
Thu, December 2, 2010
Wed, December 1, 2010
Tue, November 30, 2010
[ Tue, Nov 30th 2010 ]: Market Wire
2005 Certification
Mon, November 29, 2010
Thu, November 25, 2010
Wed, November 24, 2010
Tue, November 23, 2010
Mon, November 22, 2010
Sat, November 20, 2010
Fri, November 19, 2010
Thu, November 18, 2010
Wed, November 17, 2010
Tue, November 16, 2010
Mon, November 15, 2010

Array BioPharma to Present ARRY-520 / KSP Inhibitor Data at 2010 ASH Annual Meeting


  Copy link into your clipboard //health-fitness.news-articles.net/content/2010/ .. p-inhibitor-data-at-2010-ash-annual-meeting.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

BOULDER, Colo.--([ BUSINESS WIRE ])--Array BioPharma Inc. (NASDAQ: ARRY) today announced that it will present data from a Phase 1 trial of KSP inhibitor ARRY-520 in patients with relapsed/refractory multiple myeloma at the 2010 Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida on Saturday, December 4, 2010.

The abstract can be accessed through the ASH website, [ www.hematology.org/Meetings/Annual-Meeting ]. The abstract title is provided below, however, please note that according to ASH policy, all data is embargoed until the time of the beginning of the presentation. The poster will be available as a PDF after it is presented on Array's website at [ www.arraybiopharma.com ].

Event:

2010 Annual Meeting of the American Society of Hematology

Poster:

A Phase 1/2 Trial of the KSP Inhibitor ARRY-520 in Relapsed/Refractory Multiple Myeloma (Publication #1959)

Date:

Saturday, December 4, 2010

Time:

5:30 a" 7:30 p.m. E.T.

Location:

Orange County Convention Center, Hall A3/A4, Poster Board no.: I-939

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at significant unmet medical needs. For more information on Array, please go to [ www.arraybiopharma.com ].


Publication Contributing Sources